Drug recall · February 12, 2025
Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL recall
Why: Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL, Single Dose prefilled syringe, packaged as a) 1 syringe in 1 CARTON, NDC 63459-910-11, Blister NDC 63459-910-12; (b)10 syringes in 1 CARTON, NDC 63459-910-15, Blister NDC 63459-910-12; (c) 1 syringe in 1 CARTON, NDC 63459-910-17 without safety guard and blister, Rx Only, Manufactured by: UAB Teva Baltics, Vilnius, Lithuania. Distributed by Teva Pharmaceuticals USA, Inc. North Wales PA 19454. Product of Israel.
- Lots / codes
Lot # (a) 135738, (b) 137149, (c) 137148, Exp. date 09/30/2025
- Quantity
- 34,636 cartons
- Company
- Teva Pharmaceuticals USA, Inc, Parsippany, NJ
- Distribution
- Product was distributed nationwide.
- Initiated
- January 10, 2025 · Voluntary: Firm initiated
- Classified
- February 4, 2025
- Reported
- February 12, 2025
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.